<DOC>
	<DOCNO>NCT00396318</DOCNO>
	<brief_summary>This Phase III , open-label , single-arm study conduct 43 center United States Canada . 251 adult pediatric patient dysfunctional central venous catheter ( CVCs ) enrol study treat one two dos tenecteplase .</brief_summary>
	<brief_title>A Study Tenecteplase Restoration Function Dysfunctional Central Venous Catheters</brief_title>
	<detailed_description />
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Clinically stable , opinion investigator CVC occlusion Able fluid infuse volume necessary instill study drug CVC Able 3 mL blood ( patient weigh ≥ 10 kg ) 1 mL blood ( patient weigh &lt; 10 kg ) withdrawn select CVC follow patient reposition Selected study CVC insert &lt; 2 day prior treatment Selected study CVC implant specifically hemodialysis ( HD ) internally coat therapeutic agent Use power injector select study CVC study drug treatment Evidence mechanical , nonthrombotic occlusion select study CVC ( e.g. , kink catheter suture constrict catheter ) Previously treat study tenecteplase catheter clearance trial Use investigational drug therapy within 28 day prior treatment Use fibrinolytic agent ( e.g. , alteplase , tenecteplase , reteplase , urokinase ) within 24 hour prior treatment Known pregnant breastfeeding screen Known bacteremia know suspected infection CVC catheter Known history intracranial hemorrhage ( within previous 3 year ) , intracranial aneurysm , arteriovenous malformation Use heparin ( unfractionated low molecular weight ) anticoagulant within 24 hour prior treatment , except heparin use prophylaxis intermittent lowdose , continuous infusion heparin maintain catheter vessel patency Subjects treat warfarin : international normalized ratio ( INR ) ≥ 3.0 within 7 day prior Visit 1 , target INR range allow INR ≥ 3.0 Initiation increase dose Plavix® ( clopidogrel bisulfate ) within 7 day prior treatment At high risk bleed event embolic complication ( i.e. , recent pulmonary embolus , deep vein thrombosis , endarterectomy , clinically significant righttoleft shunt ) opinion investigator , know condition bleed constitutes significant hazard Known hypersensitivity tenecteplase component formulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>TNKase</keyword>
	<keyword>CVA</keyword>
	<keyword>CVAD</keyword>
	<keyword>Central venous access catheter</keyword>
</DOC>